Segments

9 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

SEGMENTS

SEGMENTS

We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:

	For the three months ended September 30,				For the nine months ended September 30,
(In thousands)	2020		2019		2020		2019
Revenue from services:
Pharmaceutical	$	—	$	—	$	—	$	—
Diagnostics	382,498		181,139		804,309		538,488
Corporate	—		—		—		—
	$	382,498	$	181,139	$	804,309	$	538,488
Revenue from products:
Pharmaceutical	$	28,702	$	26,161	$	89,133	$	80,143
Diagnostics	—		—		—		—
Corporate	—		—		—		—
	$	28,702	$	26,161	$	89,133	$	80,143
Revenue from transfer of intellectual property and other:
Pharmaceutical	$	6,819	$	20,676	$	31,057	$	58,165
Diagnostics	10,045		—		16,240		—
Corporate	—		796		—		796
	$	16,864	$	21,472	$	47,297	$	58,961
Operating income (loss):
Pharmaceutical	$	(14,425)	$	(14,232)	$	(34,546)	$	(52,265)
Diagnostics	46,172		(16,363)		68,975		(77,945)
Corporate	(9,808)		(8,416)		(26,071)		(31,378)
	$	21,939	$	(39,011)	$	8,358	$	(161,588)
Depreciation and amortization:
Pharmaceutical	$	7,316	$	7,673	$	21,556	$	22,580
Diagnostics	13,720		16,116		43,739		48,647
Corporate	—		16		—		54
	$	21,036	$	23,805	$	65,295	$	71,281
Loss from investment in investees:
Pharmaceutical	$	(110)	$	(294)	$	(433)	$	(2,419)
Diagnostics	—		—		—		—
Corporate	—		—		—		—
	$	(110)	$	(294)	$	(433)	$	(2,419)
Revenues:
United States	$	400,778	$	189,485	$	847,539	$	558,688
Ireland	8,988		22,968		37,736		65,675
Chile	11,062		8,436		33,064		25,352
Spain	3,713		4,172		12,005		13,466
Israel	1,119		1,938		4,010		8,822
Mexico	2,280		1,642		5,987		5,231
Other	124		131		398		358
	$	428,064	$	228,772	$	940,739	$	677,592

(In thousands)	September 30, 2020		December 31, 2019
Assets:
Pharmaceutical	$	1,151,065	$	1,174,639
Diagnostics	1,176,028		1,035,112
Corporate	44,198		99,521
	$	2,371,291	$	2,309,272
Goodwill:
Pharmaceutical	$	240,986	$	237,131
Diagnostics	434,809		434,809
Corporate	—		—
	$	675,795	$	671,940

No customer represented more than 10% of our total consolidated revenue during the nine months ended September 30, 2020 and 2019. As of September 30, 2020 and December 31, 2019, no customer represented more than 10% of our accounts receivable balance.